RBC Capital raises Verastem stock price target to $19 on G12D data
RBC Capital raised its price target for Verastem Inc. (VSTM) to $19.00 from $14.00, citing positive data for its G12D drug candidate. The firm maintains an Outperform rating, noting potential market share and undervaluation. Verastem's Q2 2026 earnings showed a 34% revenue increase, surpassing estimates. Analysts have mixed price targets but generally positive ratings.
How this was made
The 30-second read
Why it matters
Analyst upgrades and price target hikes often trigger short-term buying pressure, especially for small-cap biotech stocks with positive trial data.
Market read
The article provides fresh analyst guidance and trial data, offering a catalyst for VSTM's stock movement.
What to watch
Potential dilution from future financing rounds and competition from other KRAS inhibitors may temper the rally.
Background
Verastem reported Q2 2026 revenue of $25.1M, beating estimates, and presented new KRAS G12D data at a R&D day.
Ticker impact
RBC Capital raised its price target on Verastem Inc. (VSTM) to $19 from $14, citing new RAS G12D drug data and Q2 earnings beat.
likely upward pressure as investors price in the higher target and positive trial data
The new $19 target represents a 147% upside from the current $7.71 price, and the upgrade is based on fresh clinical data and better-than-expected Q2 revenue.
Market effects
Positive data on KRAS G12D inhibitors may lift other biotech firms developing similar oncology therapies.
US biotech sector could see modest gains as investors reassess pipeline valuations.
Limited to biotech investors; no broad market effect.
Counterpoint
The drug's tolerability concerns and lack of profitability could limit upside despite the higher target.
Key entities
- companyVerastem Inc.
Biotech firm developing KRAS G12D inhibitor VS-7375.
- analystRBC Capital
Investment bank that raised the price target.
